Immunotyping inflammatory arthritis: Blood and synovial fluid cellular and molecular biomarkers in immune-mediated inflammatory diseases

Completed

• Conditions: arthritis; inflammatory systemic diseases; 10003816; 10023213

• Registration Number: NL-OMON47311
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 700

Inclusion Criteria

- patients with an immune-mediated disease (e.g. systemic lupus, rheumatoid arthritis, gout)
- patients of at least 18 years old

Exclusion Criteria

- patients who are unable to give informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>is to identify immunological alterations in the PB and SF of patients with<br /><br>various forms of inflammatory arthritis and systemic inflammatory diseases and<br /><br>to correlate these alterations with diagnosis, disease stage, prognosis, and<br /><br>treatment response. We thereby aim to identify and validate novel biomarkers<br /><br>that can be used fro personalized medicine in IMIDs</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N.A.</p><br>